CClinicalTrials.gg
CompletedNCT01601158Updated Jan 9, 2014

Umbilical Cord Blood Therapy for Children With Global Developmental Delay

An interventional study of Umbilical Cord Blood administration and Active Rehabilitation in Global Developmental Delay, sponsored by MinYoung Kim, M.D.. Completed at 1 site in Korea, Republic of. Open to participants aged 6 Months to 15 Years. Per ClinicalTrials.gov, last updated 2014-01-09.

Sponsored by MinYoung Kim, M.D. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
6 Months to 15 Years
Sex
All
01

Study summary

This open-label study aims to evaluate the safety and efficacy of umbilical cord blood therapy for children with global developmental delay.

Read the detailed description

Global developmental delay (GDD) is a subset of developmental disabilities defined as significant delay in two or more of the following developmental domains: gross/fine motor, speech/language, cognition, social/personal, and activities of daily living.

Umbilical cord blood has been used for inherited metabolic diseases that feature global developmental delay and many experimental animal studies have revealed umbilical cord blood is useful to repair neurological impairments in brain.

02

Conditions studied

  • Global Developmental Delay

Keywords

  • Global developmental delay
  • Umbilical cord blood
  • Rehabilitation
03

In context

Lead sponsor

MinYoung Kim, M.D. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Global developmental delay
  • Willing to comply with all study procedure

Exclusion criteria

Exclusion Criteria:

  • Medical instability including pneumonia or renal function at enrollment
  • Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
  • Uncontrolled persistent epilepsy
  • Not eligible according to the principal investigator
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Umbilical Cord Blood and Rehabilitation

    Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation

    Biological: Umbilical Cord Blood administration · Other: Active Rehabilitation

Interventions

  • BiologicalUmbilical Cord Blood administration

    The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.

    Also known as: Donated Umbilical Cord Blood Units from Affiliated Cord Blood Bank

  • OtherActive Rehabilitation

    All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.

06

What researchers measure

Primary outcomes

  1. Changes in Cognition

    Korean Wechsler Preschool and Primay Scale of Intelligence (K-WPPSI) (Higher value means better cognitive function (K-WPPSI: below 70 - worst, over 130 - best). The investigators will report K-WPPSI at each assessment time points.

    Time frame: Baseline - 6 months - 12 months

  2. Changes in Cognitive Neurodevelopmental Outcome

    Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scales (Higher value means better cognitive function, K-BSID-II mental scale raw score: 0 - worst, 178 - best). The investigators will report K-BSID-II Mental Scale raw scores at each assessment time points.

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

Secondary outcomes

  1. Changes in Motor Performance

    GMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0\~100, Higher value means better motor quality). The investigators will report GMPM scores at each assessment time points.

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

  2. Changes in Standardized Gross Motor Function

    GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying \& rolling, sitting, crawling \& kneeling, standing, walking, running \& jumping (range: 0\~100 , Higher value means better gross motor function). The investigators will report GMFM scores at each assessment time points.

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

  3. Changes in Motor Neurodevelopmental Outcome

    Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scales (higher value means better motor function: 0 - worst, 111 - best). The investigators will report K-BSID-II Motor Scale raw scores at each assessment time points.

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

  4. Changes in Functional Independence in Daily Activities

    WeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher scores mean more independent performance in daily activities. The investigators will report total WeeFIM scores measured at each assessment time points.

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

  5. Changes in Visual Perception Test

    We will evaluate visual perception function with one of three measures: DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). All can be scored as percentile rank from 0 to 100. Higher values mean better visual perception ability

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

  6. Changes in Muscle Strength

    Summation of MMT (manual muscle strength test score): summated scores of the manual muscle strength test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 \~ 160) Higher scores mean better muscle strength. Categories of outcome table will be summation of MMT scores measured at each assessment time point.

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

  7. Changes in Functional Performance in Daily Activities

    Pediatric Evaluation of Disability Inventory (PEDI) for assessing functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). We will report 2 scales and 3 domains of each scale: a Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) which are divided respectively into 3 domains: self care, mobility, and social function. Categories of outcome table will be each domain scores measured at each assessment time point.

    Time frame: Baseline - 1 month - 3 months - 6 months - 12 months

  8. Changes in Language Evaluation

    Sequenced Language Scale for Infant (SELSI), Preschool Receptive-Expressive Language Scale (PRES) or Korean Western Aphasia Battery (K-WAB) will be used depending on age and function.

    Time frame: Baseline - 6 months - 12 months

07

Study locations

1 site
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Gyeonggi-do 463-712, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01601158
Lead sponsor
MinYoung Kim, M.D.
Responsible party
MinYoung Kim, M.D. (Associate Professor, Bundang CHA Hospital) — Sponsor-investigator
First posted
May 17, 2012
Start date
May 2012
Primary completion
Aug 2013
Completion
Aug 2013
Last update
Jan 9, 2014

Study contacts

Minyoung Kim, M.D., Ph.D.
principal investigator · CHA University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion